At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun.
If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.
Rondo Therapeutics is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti tumor response.
If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.
Rondo Therapeutics is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti tumor response.
Location: United States, California, Alameda
Employees: 11-50
Total raised: $67M
Founded date: 2021
Investors 2
| Date | Name | Website |
| - | Red Tree V... | redtreevc.... |
| 10.07.2026 | Canaan Par... | canaan.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.03.2022 | Series A | $67M | Red Tree V... |
Mentions in press and media 4
| Date | Title | Description |
| 13.05.2026 | Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody Targeting Nectin-4 in Advanced Solid Tumors | Novel CD28 x Nectin-4 bispecific designed to overcome limitations of ADCs through durable and well-tolerated tumor-directed immune co-stimulation Milestone marks Rondo Therapeutics’ transition to a clinical-stage company HAYWARD, Calif.--(... |
| 04.12.2024 | Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors | - Lilly is granted exclusive worldwide rights to develop a CD28-co-stimulatory therapeutic for a defined cancer target – Rondo Therapeutics receives upfront cash and is eligible to receive milestone payments and tiered royalties December 04... |
| 02.07.2024 | Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics | HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately-held biopharmaceutical company advancing next-generation immuno-oncology platforms, announces the appointment of Steven James to its Board of Directors. Mr. James brings over... |
| 02.03.2022 | Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors | SAN FRANCISCO, March 2, 2022 /PRNewswire/ -- Rondo Therapeutics, a biopharmaceutical company advancing a next-generation immuno-oncology platform for treating solid tumors, today announced the closing of an oversubscribed $67 million Series... |